Abbott: CardioMEMS Device Shows Potential Benefits In New Groups Of Patients

Abbott (ABT) reported results of the GUIDE-HF clinical trial which assessed the benefits of the CardioMEMS HF System in an expanded patient population not currently approved for the device. The company said the trial data suggests CardioMEMS can improve care for more types of patients battling heart failure and reduce hospitalizations, especially for patients suffering from earlier stages of the disease.

CardioMEMS is currently approved for use in NYHA Class III patients with a prior heart failure hospitalization within the last year. The GUIDE-HF study examined patients with NYHA Class II and Class IV heart failure to evaluate the device in patients in earlier or later-stage disease progression.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port. Affco USA is recalling around 24,461 pounds of frozen raw lamb shoulder products that were not presented for import re-inspection into the U.S., the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves the frozen raw lamb shoulder items that were imported on July 12, 2021. American Express Company (AXP) reported an increase in profit for the third quarter that also topped Wall Street estimates. Consolidated total revenues net of interest expense rose 25 percent year-on-year, primarily reflecting growth in Card Member spending, as well as a rise in the average discount...
Follow RTT